The Population Genetics Analysis Program (PGAP) Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract, administered by the National Institute of Allergy and Infectious Diseases (NIAID), supports advanced genetic research focused on understanding human immune response variations. The contract enables scientific investigations that explore genetic correlations with individual immunological reactions to infectious pathogens and vaccination scenarios. Specifically, the vehicle supports research designed to replicate and validate previously identified human genotype-phenotype associations, with a primary objective of enhancing medical understanding of genetic factors influencing infectious disease susceptibility and immune system performance.
The PGAP Master IDIQ, originally awarded on June 30, 2010, with a last order date of June 29, 2017, facilitates complex genetic research task orders within the biomedical research domain. While specific task order details are not provided, such contracts typically range in value from $500,000 to $5 million, with durations spanning 12-36 months. Research would likely be conducted at academic medical centers, research universities, and specialized infectious disease laboratories, with potential set-aside considerations for small business research entities or minority-serving institutions. The primary funding agency, the National Institutes of Health (NIH), would coordinate task order competitions among pre-qualified prime contractors with demonstrated expertise in population genetics, immunology, and infectious disease research methodologies.